News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Shoff brings over 30 years of international experience in in vitro diagnostics, healthcare distribution and veterinary diagnostics
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Subscribe To Our Newsletter & Stay Updated
